Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

gnosed AML, between 60 and 76 years of age. A second Phase 2 study of CPX-351 in patients 18-60 years old with AML in first relapse is also being initiated.

About Acute Myeloid Leukemia (AML)

The National Cancer Institute defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow. In 2008, the American Cancer Society's Cancer Facts and Figures estimates 13,290 new cases of AML and 8,820 deaths.

About Celator

Celator(R) Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com.

List of abstracts:

ASH Abstract # 942

Mayer L, Wahseng L, Dos Santos N, et al. Synergistic cytarabine:daunorubicin ratios
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 With the ... at Ground Zero, the Ground Zero Museum Workshop in the ... tour bookings. Says the Museum Workshop's Carole Barnes, "We have ... on all the major travel sites who sell us so ... now crystal clear as to what we do and what ...
(Date:7/30/2014)... 2014 The Dr. Hector P. Garcia ... announced the proposed naming of the new primary care ... Garcia Family Health Center. , The proposed 40,000 sq. ... including comprehensive chronic disease management programs, pharmacy services and ... pioneering medical home model center. , Dr. Hector P. ...
(Date:7/30/2014)... 2014We have pills to ease pain, to cure infection, to ... enhance our sexual and athletic prowess. Why do pills play ... benefit from taking fewer pills? This provocative topic is explored ... Fantasy of Pills in Modern Medicine ," published in ... publication from Mary Ann Liebert, Inc., publishers. The article is ...
(Date:7/30/2014)... Today, Gen. Arthur T. Dean, Chairman ... (CADCA) , the nation’s leading substance abuse prevention organization, ... New York Times Editorial Board’s call for marijuana ... , “CADCA is disappointed in the New York Times ... marijuana legalization. The move is shortsighted and completely disregards ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2
... including parents, relatives and friends of the 94 children, who ... today paid floral homage// to the departed on the second ... the people in paying homage. ,An eye donation ... front of the school to pay homage to the children ...
... Jefferson Medical College and Jefferson's Kimmel Cancer Center have ... role// in the spread of bladder cancer. This discovery ... drug to treat this form of cancer. ... promote cell proliferation, but instead promotes migration and invasion ...
... soft corner for sweets may end up eating more fruit compared ... Cornell University//. ,"If we know a person likes ... predict what other types of foods he or she might prefer," ... that studies the psychology behind what people eat and how often ...
... are suffering from long-term spinal cord injuries, with more than ... study appearing in the July 12th issue of the Journal ... providing evidence that a combination of treatments could lead to ... result would be a return of functional activity. ...
... of all babies born in the United States are ... ,Now, the March of Dimes and the American ... American College of Medical Genetics calling for expanded screening ... ,UAB maternal and child health expert Russell Kirby, Ph.D., ...
... sleep and exercise for glowing skin. Precious stones are the ... fad of gem stone facials is fast catching on in ... offering facials that use 'bhasm' (ash) of stones like rubies, ... ,"Bhasm of these stones is used in ayurveda to treat ...
Cached Medicine News:Health News:Protein holds clue in the spread of bladder cancer 2Health News:Astro Gem Therapy: The Latest Beauty Secret for Glowing Skin 2
(Date:7/29/2014)... OAKS, Calif., July 29, 2014 Amgen (NASDAQ: ... the second quarter of 2014. Key results include: ... with 8 percent product sales growth driven by strong ... Kyprolis ® (carfilzomib), Prolia ® (denosumab) and ... 25 percent to $2.37, driven by higher revenues and ...
(Date:7/29/2014)... RIDGE, N.J. , July 29, 2014 ... biopharmaceutical company focused on the Phase 3 clinical development ... actively controllable antithrombotic drug system, today announced that it ... on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT ... corporate highlights. Interested participants and investors may ...
(Date:7/29/2014)... ST. PAUL, Minn. , July 29, 2014 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... Conference Call Details The second quarter conference ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
...   Delcath Systems, Inc. (NASDAQ: DCTH ) ... Board. "As a widely respected hepatologist ... (ILCA), Dr. Gores will contribute a wealth of clinical ... our Medical Advisory Board," said Eamonn P. Hobbs, CEO ...
... PLEASANTON, Calif., Dec. 21, 2011  TriReme Medical, Inc. ... the treatment of complex vascular disease, announced today ... U.S. Food and Drug Administration to market its ... of occluded peripheral arteries. Chocolate was developed in ...
Cached Medicine Technology:Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4TriReme Medical, Inc. Receives FDA 510(K) Clearance for Chocolate PTA Balloon Catheter 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: